Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A placebo controlled trial of fluticasone propionate in asthmatic children
European Journal of Pediatrics, Volume 152, No. 10, Year 1993
Notification
URL copied to clipboard!
Description
Fluticasone propionate is a synthetic steroid for use by the inhaled route. It's high topical potency and low systemic bioavailability make it suitable for use in asthmatic children. A total of 258 children were randomised in a double-blind study to receive fluticasone propionate (50 μg bd) as the dry powder formulation inhaled via a Diskhaler inhaler, or matched placebo (with current therapy) for 4 weeks throughout which time diary cards were completed. During clinic visits lung function and adrenal function were measured. Fluticasone propionate produced a significantly greater increase in morning peak expiratory flow rate (PEFR) (adjusted mean difference over days 1-28, 17 l/min (95% CI; 10, 24);P<0.001) and evening PEFR (adjusted mean difference over days 1-28, 16 l/min (95% CI; 9, 23);P<0.001). In addition, diary card symptom scores, beta2-agonist rescue and clinic lung function improved significantly on fluticasone propionate. There were few adverse events and basal plasma cortisol remained within the normal range. In conclusion fluticasone propionate at 50 μg bd is superior to placebo (current therapy) in the treatment of childhood asthma with no evidence of adverse effects. © 1993 Springer-Verlag.
Authors & Co-Authors
MacKenzie, C. A.
United Kingdom, Sheffield
The University of Sheffield
Weinberg, Eugene G.
South Africa, Cape Town
Red Cross War Memorial Children's Hospital
Tabachnik, E.
Israel, Rehovot
Kaplan Hospital Israel
Taylor, M.
Ireland, Dublin
Tallaght University Hospital
Havnen, Jacob
Norway, Stavanger
Paediatric Department
Crescenzi, K.
United Kingdom, Brentford
Glaxosmithkline Plc.
Statistics
Citations: 22
Authors: 6
Affiliations: 6
Identifiers
Doi:
10.1007/BF02073387
ISSN:
03406199
e-ISSN:
14321076
Research Areas
Disability
Health System And Policy
Maternal And Child Health